Defunct Company
Total Trials
5
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,083
NCT00948142
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
Phase: Phase 2
Role: Lead Sponsor
Start: Aug 31, 2009
Completion: Mar 31, 2010
NCT01756924
Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection
Start: Dec 31, 2012
Completion: Jul 31, 2014
NCT02570490
Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Phase: Phase 3
Start: Nov 30, 2015
Completion: Nov 30, 2016
NCT02569541
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
Phase: Phase 2/3
Start: Dec 31, 2015
Completion: Feb 21, 2019
NCT05105035
Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients
Start: Jun 14, 2022
Completion: Oct 10, 2023